Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

Gerben R. Borst; Ramya Kumareswaran; Hatice Yücel; Seyda Telli; Trevor Do; Trevor McKee; Gaetano Zafarana; Jos Jonkers; Marcel Verheij; Mark J. O’Connor; Sven Rottenberg; Robert G. Bristow

doi:10.18632/oncotarget.27476

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

PDF | How to cite

Oncotarget. 2020; 11:1573-1574. https://doi.org/10.18632/oncotarget.27476

Metrics: PDF 1235 views | ?

Gerben R. Borst^1,2,3, Ramya Kumareswaran^1,2, Hatice Yücel^1,2,3, Seyda Telli^1,2, Trevor Do^1,2, Trevor McKee^1,2, Gaetano Zafarana^1,2, Jos Jonkers⁴, Marcel Verheij³, Mark J. O’Connor⁵, Sven Rottenberg^4,6 and Robert G. Bristow^1,2

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
² Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada
³ Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands
⁴ Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Molecular Biology, Amsterdam, The Netherlands
⁵ Oncology, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom
⁶ Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland

Published: April 28, 2020

This article has been corrected: Due to errors in image processing, in the top panel of Figure 4D, the top row showing an example of 2 H&E sections of 2 tumors was accidentally switched in position. The corrected Figure 4D is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:87638–87646. DOI: https://doi.org/10.18632/oncotarget.20936.

Figure 4: (A) The percentage of cells which are EF5 positive (i. e. red regions are hypoxic in Figure 4C) is significantly lower following neoadjuvant Olaparib treatment (black diamonds) when compared to the untreated control tumors (grey triangles). (B) The vessel density in olaparib (black diamonds) treated and control tumors (grey triangles) are different in the oxic regions within the tumor. (C) Hypoxic (positive EF5) area indicated by the white triangle and CD31 (vessel) is indicated by the white arrow. (D) I. Two H&E staining slides of a control (left) and neoadjuvantly (right) treated tumor of about 9 mm in length (scale bar of 1 mm is picture in the left top corner). H&E staining was executed to discriminate the different tissue types in the tumor. II. Discrimination: orange=tumor tissue, blue=necrotic tissue, green=normal breast tissue, brown=artefact, grey=mesenchymal tissue. III. EF5 staining of a control (left) and neoadjuvantly (right) treated tumor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27476

Publication Alerts

Corrections:

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model